These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32819305)

  • 21. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.
    Esteva FJ; Stebbing J; Wood-Horrall RN; Winkle PJ; Lee SY; Lee SJ
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):505-514. PubMed ID: 29330636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients.
    Nodehi RS; Kalantari B; Raafat J; Ansarinejad N; Moazed V; Mortazavizadeh SMR; Hosseinzadeh M; Ghaderi B; Jenabian A; Qadyani M; Haghighat S; Allahyari A; Mirzania M; Seghatoleslami M; Payandeh M; Alikhasi A; Kafi H; Shahi F
    BMC Pharmacol Toxicol; 2022 Jul; 23(1):57. PubMed ID: 35902898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
    Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
    JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer.
    Kothari R; Doshi M; Chaithanya PK; Ct S; Kumar A; Mallavarapu KM; Nagarkar R; Mahobia V; Bhatt N; Priyadarshini KL; Gogia A; Maksud T; Prasad S; Velavan K; L K R; Ss P; Talreja V; Kalra K; Nemade B; Dastidar AG; Gupta T; Patil T; Bondarde S; Patel P; Gupta S; Biswas G; Vaghela M; Mahato P; Parekh H; Kalloli M; Shetty R; Prakash G; Goel A; Mandal S; Choudhury T; Jain M; Goswami C; H M YK; Mukherjee KK; Shrivastava R; Parmar D
    Clin Breast Cancer; 2024 Oct; 24(7):639-646.e2. PubMed ID: 39069436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects.
    Hanes V; Chow V; Stewart T; Puri A
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):879-886. PubMed ID: 34355250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
    Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Shparyk Y; Moiseyenko V; Bello M; Semiglazov V; Lee Y; Lim J
    Eur J Cancer; 2018 Apr; 93():19-27. PubMed ID: 29448072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
    BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects.
    Farmahini Farahani M; Maghzi P; Jafari Aryan N; Payandemehr B; Soni M; Azhdarzadeh M
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1443-1450. PubMed ID: 33016783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.
    Lammers PE; Dank M; Masetti R; Abbas R; Hilton F; Coppola J; Jacobs I
    Br J Cancer; 2018 Aug; 119(3):266-273. PubMed ID: 30002437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
    Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
    Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.
    Pivot X; Georgievich MA; Shamrai V; Dzagnidze G; Soo Hoo HF; Kaewkangsadan V; Petrelli F; Villanueva C; Nikolaevich LO; Hii J; Kim J; Pradhan S; Jaison L; Feyaerts P; Kaufman L; Derde MP; Bonamy GMC; Deforce F; Cox DG
    JAMA Oncol; 2022 May; 8(5):698-705. PubMed ID: 35238873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
    Ocana A; Gil-Martin M; Antolín S; Atienza M; Montaño Á; Ribelles N; Urruticoechea A; Falcón A; Pernas S; Orlando J; Montero JC; Escudero MJ; Benito S; Caballero R; Carrasco E; Rojo F; Pandiella A; Ruiz-Borrego M
    Breast Cancer Res Treat; 2019 Apr; 174(3):693-701. PubMed ID: 30607629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
    Esteva FJ; Baranau YV; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskiy D; Pikiel J; Eniu AE; Li RK; Rusyn AV; Tiangco B; Lee SJ; Lee SY; Yu SY; Stebbing J
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):839-847. PubMed ID: 31428820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin
    Lickliter JD; Dadhania RN; Trivedi RK; Naveen Kumar SR; Reddy PK
    Indian J Med Res; 2021 Mar; 154(3):509-519. PubMed ID: 35142643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials.
    Cargnin S; Shin JI; Genazzani AA; Nottegar A; Terrazzino S
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):577-588. PubMed ID: 33005979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.